CUE NASDAQ
Cue Biopharma, Inc.
1W: -18.6%
1M: -5.2%
3M: -21.3%
YTD: +152.7%
1Y: +17.8%
3Y: -65.1%
5Y: -94.1%
$25.57
+0.32 (+1.27%)
Weekly Expected Move ±18.5%
$16
$21
$26
$30
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-10-01
Earliest Filing
2025-12-19
Latest Filing
partner: 7
licensee: 1
Counterparties (Filed by CUE)
8 relationshipsCompanies named in CUE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ImmunoScape Pte. Ltd. | — | partner | Counterparty to collaboration and license agreements providing upfront and time-based payments. | 2025-12-19 | View |
| ImmunoScape Pte. Ltd. | — | partner | Entered into a collaboration and license agreement to develop a novel Seed-and-Boost immunotherapy combining Cue Biophar | 2025-11-06 | View |
| MIL 40G, LLC | — | licensee | Licensor in a license agreement amendment regarding rental rates and term extension | 2025-07-01 | View |
| Boehringer Ingelheim International GmbH | — | partner | Counterparty to a Collaboration and License Agreement providing upfront payment | 2025-04-15 | View |
| Boehringer Ingelheim International GmbH | — | partner | Entered into a Collaboration and License Agreement for B cell depletion molecules | 2025-04-14 | View |
| Albert Einstein College of Medicine | — | partner | Amended license agreement to consent to sublicense and adjust upstream payments | 2025-04-14 | View |
| Jefferies LLC | JEF | partner | Acted as sales agent for the Open Market Sale Agreement. | 2021-10-01 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Previous sales agent whose agreement was terminated. | 2021-10-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-14 | Earnings Release | View | |
| 2026-08-03 | Officer/Director Change | View | |
| 2026-07-10 | Material Agreement; Unregistered Equity Sales; Officer/Director Change; Other Events; Exhibits | Agreement | View |
| 2026-06-03 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-06-02 | Officer/Director Change; Other Events | View | |
| 2026-05-14 | Exhibits | View | |
| 2026-05-01 | Material Agreement; Unregistered Equity Sales; Officer/Director Change; Other Events; Exhibits | Agreement | View |
| 2026-04-22 | Bylaws Amendment | View | |
| 2026-04-13 | Shareholder Vote | View | |
| 2026-04-07 | Other Events | View | |
| 2026-03-27 | Officer/Director Change | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-18 | Other Events | View | |
| 2026-02-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-19 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-24 | Regulation FD Disclosure | View | |
| 2025-11-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR